Keynote Presentation
Duane Roth Award Lecture
Engineering T-Cells: The Sky is the Limit
Carl June, MD University of Pennsylvania School of Medicine
Carl June, MD Richard W. Vague Professor of Immunotherapy
Director of the Center for Cellular Immunotherapies
Perelman School of Medicine
Director of the Parker Institute for Cancer Immunotherapy
University of Pennsylvania
Carl June is the Director of the Center for Cellular Immunotherapies at the Perelman School of Medicine, and Director of the Parker Institute for Cancer Immunotherapy at the University of Pennsylvania. He maintains a research laboratory that studies various mechanisms of lymphocyte activation that relate to immune tolerance and adoptive immunotherapy for cancer and chronic infection. In 2011, his research team published findings detailing a new therapy in which patients with refractory and relapsed chronic lymphocytic leukemia were treated with genetically engineered versions of their own T cells. The treatment has also now also been used with promising results to treat children with refractory acute lymphoblastic leukemia. He has published more than 350 manuscripts and is the recipient of numerous prizes and honors, including election to the Institute of Medicine in 2012 and the American Academy of Arts and Sciences in 2014, the Paul Ehrlich and Ludwig Darmstaedter Prize (shared w J. Allison), the Novartis Prize in Immunology (shared w Z. Eshaar and S. Rosenberg), the Karl Landsteiner Memorial award, and a lifetime achievement award from the Leukemia and Lymphoma Society.